Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

T Berger, I Elovaara, S Fredrikson, C McGuigan, L Moiola, KM Myhr, C Oreja-Guevara, I Stoliarov, UK Zettl

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs). In clinical trials, alemtuzumab demonstrated efficacy in treatment-naïve patients with active RRMS and those relapsing on prior DMTs, with a consistent and manageable safety and tolerability profile. The European Union indication provides physicians with significant flexibility regarding treatment decisions, affording the opportunity for individualized treatment. Thus, alemtuzumab may be an appropriate treatment choice across a broad range of patients with RRMS, including, for example, treatment-naïve patients with active disease, patients with highly active disease, or for patients relapsing on prior DMTs. There are several practicalities to consider when using alemtuzumab, including the unique dosing regimen, administered via intravenous infusion on 5 consecutive days at baseline and on 3 consecutive days 12 months later, and as-needed retreatment (3 consecutive days at least 12 months after the last course) in cases of disease recurrence. Additionally, routine monthly monitoring is required for up to 48 months after the last infusion to promptly identify potentially serious autoimmune adverse events. Given these considerations, it is beneficial to gain insight into how alemtuzumab is being used in the real-world clinical setting. Here, we report recommendations from European multiple sclerosis experts regarding best practices for alemtuzumab treatment, including management of adverse events and compliance with ongoing safety monitoring requirements. © 2016 The Author(s)
Original languageEnglish
Pages (from-to)33-50
Number of pages18
JournalCNS Drugs
Volume31
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Therapeutics
European Union
alemtuzumab
Safety
Antibodies, Monoclonal, Humanized
Retreatment
Practice Guidelines
Intravenous Infusions
Clinical Trials
Physicians
Recurrence

Cite this

Berger, T., Elovaara, I., Fredrikson, S., McGuigan, C., Moiola, L., Myhr, KM., ... Zettl, UK. (2017). Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. CNS Drugs, 31(1), 33-50. https://doi.org/10.1007/s40263-016-0394-8

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. / Berger, T; Elovaara, I; Fredrikson, S; McGuigan, C; Moiola, L; Myhr, KM; Oreja-Guevara, C; Stoliarov, I; Zettl, UK.

In: CNS Drugs, Vol. 31, No. 1, 2017, p. 33-50.

Research output: Contribution to journalArticle

Berger, T, Elovaara, I, Fredrikson, S, McGuigan, C, Moiola, L, Myhr, KM, Oreja-Guevara, C, Stoliarov, I & Zettl, UK 2017, 'Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts', CNS Drugs, vol. 31, no. 1, pp. 33-50. https://doi.org/10.1007/s40263-016-0394-8
Berger, T ; Elovaara, I ; Fredrikson, S ; McGuigan, C ; Moiola, L ; Myhr, KM ; Oreja-Guevara, C ; Stoliarov, I ; Zettl, UK. / Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. In: CNS Drugs. 2017 ; Vol. 31, No. 1. pp. 33-50.
@article{97b7b01e83334974affc4928e30d6dce,
title = "Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts",
abstract = "Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs). In clinical trials, alemtuzumab demonstrated efficacy in treatment-na{\"i}ve patients with active RRMS and those relapsing on prior DMTs, with a consistent and manageable safety and tolerability profile. The European Union indication provides physicians with significant flexibility regarding treatment decisions, affording the opportunity for individualized treatment. Thus, alemtuzumab may be an appropriate treatment choice across a broad range of patients with RRMS, including, for example, treatment-na{\"i}ve patients with active disease, patients with highly active disease, or for patients relapsing on prior DMTs. There are several practicalities to consider when using alemtuzumab, including the unique dosing regimen, administered via intravenous infusion on 5 consecutive days at baseline and on 3 consecutive days 12 months later, and as-needed retreatment (3 consecutive days at least 12 months after the last course) in cases of disease recurrence. Additionally, routine monthly monitoring is required for up to 48 months after the last infusion to promptly identify potentially serious autoimmune adverse events. Given these considerations, it is beneficial to gain insight into how alemtuzumab is being used in the real-world clinical setting. Here, we report recommendations from European multiple sclerosis experts regarding best practices for alemtuzumab treatment, including management of adverse events and compliance with ongoing safety monitoring requirements. {\circledC} 2016 The Author(s)",
author = "T Berger and I Elovaara and S Fredrikson and C McGuigan and L Moiola and KM Myhr and C Oreja-Guevara and I Stoliarov and UK Zettl",
year = "2017",
doi = "10.1007/s40263-016-0394-8",
language = "English",
volume = "31",
pages = "33--50",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts

AU - Berger, T

AU - Elovaara, I

AU - Fredrikson, S

AU - McGuigan, C

AU - Moiola, L

AU - Myhr, KM

AU - Oreja-Guevara, C

AU - Stoliarov, I

AU - Zettl, UK

PY - 2017

Y1 - 2017

N2 - Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs). In clinical trials, alemtuzumab demonstrated efficacy in treatment-naïve patients with active RRMS and those relapsing on prior DMTs, with a consistent and manageable safety and tolerability profile. The European Union indication provides physicians with significant flexibility regarding treatment decisions, affording the opportunity for individualized treatment. Thus, alemtuzumab may be an appropriate treatment choice across a broad range of patients with RRMS, including, for example, treatment-naïve patients with active disease, patients with highly active disease, or for patients relapsing on prior DMTs. There are several practicalities to consider when using alemtuzumab, including the unique dosing regimen, administered via intravenous infusion on 5 consecutive days at baseline and on 3 consecutive days 12 months later, and as-needed retreatment (3 consecutive days at least 12 months after the last course) in cases of disease recurrence. Additionally, routine monthly monitoring is required for up to 48 months after the last infusion to promptly identify potentially serious autoimmune adverse events. Given these considerations, it is beneficial to gain insight into how alemtuzumab is being used in the real-world clinical setting. Here, we report recommendations from European multiple sclerosis experts regarding best practices for alemtuzumab treatment, including management of adverse events and compliance with ongoing safety monitoring requirements. © 2016 The Author(s)

AB - Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs). In clinical trials, alemtuzumab demonstrated efficacy in treatment-naïve patients with active RRMS and those relapsing on prior DMTs, with a consistent and manageable safety and tolerability profile. The European Union indication provides physicians with significant flexibility regarding treatment decisions, affording the opportunity for individualized treatment. Thus, alemtuzumab may be an appropriate treatment choice across a broad range of patients with RRMS, including, for example, treatment-naïve patients with active disease, patients with highly active disease, or for patients relapsing on prior DMTs. There are several practicalities to consider when using alemtuzumab, including the unique dosing regimen, administered via intravenous infusion on 5 consecutive days at baseline and on 3 consecutive days 12 months later, and as-needed retreatment (3 consecutive days at least 12 months after the last course) in cases of disease recurrence. Additionally, routine monthly monitoring is required for up to 48 months after the last infusion to promptly identify potentially serious autoimmune adverse events. Given these considerations, it is beneficial to gain insight into how alemtuzumab is being used in the real-world clinical setting. Here, we report recommendations from European multiple sclerosis experts regarding best practices for alemtuzumab treatment, including management of adverse events and compliance with ongoing safety monitoring requirements. © 2016 The Author(s)

U2 - 10.1007/s40263-016-0394-8

DO - 10.1007/s40263-016-0394-8

M3 - Article

VL - 31

SP - 33

EP - 50

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 1

ER -